Interesting article about Vegas 2047 and A. Hightower. Enjoy:

Advantage-play pinball aims to change casino gambling

Aaron Hightower envisions a new frontier for casino gambling. He aims to provide a dramatically different machine game that appeals not only to casual gamblers looking for fun and a chance at a jackpot but also to advantage players who rely on skill to win consistently over the long run.
His game would be a huge step beyond slot machines that carry a fixed payout percentage and involve nothing more than luck. They also could help attract players bored by standard slots.
“Gambling should be something where you have a fair chance to win,” says Hightower, vice president of gaming technology for NanoTech Gaming in Las Vegas.

“We also believe that if you want the skill to make a difference, you should be allowed to have that privilege. … Our game is designed in such a way that a top player on a given machine can be making more than the casino on that machine, and it's not an expression of something going wrong.”
NanoTech's creation is Vegas 2047, an electronic pinball machine that lets players choose the degree of luck and the degree of skill that figure into the potential payout. The company exhibited it at the 2014 Global Gaming Expo and hopes to have it in casinos by the end of the year. David G. Schwartz, director of the Center for Gaming Research at the University of Nevada Las Vegas, writes in Vegas Seven magazine that the game is an example of an attempt to change how machines and players interact.

The name Vegas 2047 pays homage to San Francisco Rush 2049, a driving-and-racing arcade game released in 1999 and set 50 years in the future. Hightower and other members of his NanoTech team worked on the Atari game.

Vegas 2047 is far more sophisticated than Rush.
Some components took a decade to develop, he says. The 3-D display includes working flippers, bumpers and balls. While a typical video-pinball game refreshes input 100 times a second, he says, Vegas 2047 refreshes 3 billion times a second. Pushes on the flipper buttons are measured in nanoseconds, making the game a true measure of pinball skill, which Hightower says is essential with money at stake.

Before playing, a player selects the size of the bet, the potential win amount and how much the pinball score should factor into the outcome. A green-and-red wheel shows the chance of winning the bet: the more green showing, the better. Betting $100 to win $5 will be successful 20 times out of 21, Hightower says. With the skill factor dialed up, a higher-than-average score increases the chance of winning.

As in a slot machine, a random generator determines the outcome. A high score does not guarantee a payout, and a player can win despite a low score.
Hightower says a handful of skilled bettors with large bankrolls could gain a long-term advantage on the game, but the casino never loses its mathematical edge . He compares it to poker, where some players consistently win at the expense of less-skilled opponents. Regardless, the casino gets its cut.
“We explicitly aim to provide an environment where the advantage player doesn't get shown the door,” Hightower says. “My view is the advantage-play market is under-served.”

The company suggests a minimum bet of $100 with a 1 percent house edge, although casinos could set either figure differently.
Hightower blames the proliferation of penny slots for creating an impression that players can't win unless they hit a life-changing jackpot.
“We're stepping outside the cultural norm,” he says. “We're fighting the mindset that's trained players that: A, you're not going to win; B, you're not going to bet enough to have that chance to win; and C, just forget about winning and have fun.”

The NanoTech approach could be applied to other games, whether newly devised ones or classics such as Donkey Kong or Pac-Man, he says. The only requirements are that the game be fair, that scores reflect the degree of skill — no secret-code shortcuts — and that games last no more than three minutes.
“It's not (our) goal to have a successful game or two or take a slice of the pie,” Hightower says. “We're looking to make a transformative kind of event where people think differently of gambling.”

Source: http://triblive.com/aande/gambling/8279731-74/game-million-payout#axzz3aT2lu82s

Don't know, I don't go there anymore.

Youtube video about Vegas 2047 by A Hightower.

Is it Walmart Shanghai? Because dozens of people have taken photographs and video of Ultraflix for weeks now here in the US.

No need to increase the AS, I see. :p

SO, RCG shares are eligible to be sold immediately according to you since they were backdated. Then, how many RCG shares are already in the OS count already? BTW, that solves the 108M shares math, doesn't it?

According to shajandr the shares were backdated, hence the explanation of the 108M shares could be easily answered.

Now, both of us know that is not the case. As I mentioned this morning, the answer to the 108M shares is in the financials (unaudited) without the need to increase the actual AS.

Now you say RCG's restricted shares were backdated, but in the financials (unaudited) they show they were issued in March 2015.

Last month you said :

It's hard not to laugh after reading the post BIG replied to.

The answer is in the latest quarterly information and disclosure statement. It's as clear as water.

Holding Period. Before you may sell any restricted securities in the marketplace, you must hold them for a certain period of time. If the company that issued the securities is a “reporting company” in that it is subject to the reporting requirements of the Securities Exchange Act of 1934, then you must hold the securities for at least six months. If the issuer of the securities is not subject to the reporting requirements, then you must hold the securities for at least one year. The relevant holding period begins when the securities were bought and fully paid for. The holding period only applies to restricted securities. Because securities acquired in the public market are not restricted, there is no holding period for an affiliate who purchases securities of the issuer in the marketplace. But the resale of an affiliate's shares as control securities is subject to the other conditions of the rule.

Rule 144 under the Securities Act of 1933

This should answer your question.

Total shares authorized: 990,000,000 as of: MARCH 31, 2015
Total shares outstanding: 847,991,093 as of: MARCH 31, 2015

Do the math...

They are restricted for 1 year unless you find a statement saying otherwise. Just assume the same details used before:

Nice chart; that is an exponential surge for searches related to Ultraflix.

RCG must likely got 0.01ish given that the share price was around 0.02ish throughout March, so stating they got shares for 0.0004 is just unreal.

Why is it toxic? You don't even know what RCG they are dealing with.

No one will lend that kind of money for the fun of it. RCG must know something we don't and they're willing to wait for their ROI.

Peter was appointed as CEO in late January 2015 when he issued his first letter to shareholders (2/6/15). There he stated:

Another great news for AMBS!

Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Methods of Administration and Compositions in the Treatment of Parkinson's Disease
GlobeNewswire 1:00 PM ET

Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that a Notice of Allowance was received from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 11/713,156 entitled, "Pharmacological Treatment of Parkinson's Disease." Upon issuance, the patent will provide additional intellectual property protection for the Company's lead product candidate, eltoprazine. The allowed patent claims cover methods and compositions for the administration of eltoprazine for the alleviation of akinesia, rigidity and/or tremor associated with Parkinson's disease.

Eltoprazine, a small molecule 5HT1A/1B partial agonist, is currently preparing to commence Phase 2b clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). PD-LID is an abnormal involuntary, movement disorder resulting from prolonged levodopa-based therapy, the most commonly prescribed treatment for Parkinson's disease (PD). PD-LID occurs in approximately 60-80% of PD patients and is one of the most difficult problems facing people with the disease. This dyskinesia can be severely disabling and impact quality of life by prohibiting the ability to perform routine daily functions.

"This Notice of Allowance for eltoprazine in Parkinson's is a meaningful addition to the intellectual property estate we have established related to eltoprazine and comes at an important time as we are gearing up to commence enrollment and patient dosing in our Phase 2b program in PD-LID," said Gerald E. Commissiong, President & CEO of Amarantus. "We believe eltoprazine has tremendous potential as an important therapy to address a significant unmet need and improve the quality of life for individuals with Parkinson's disease and their families."

Amarantus expects to initiate patient enrollment and dosing in a 60-subject Phase 2b clinical study with eltoprazine in individuals with PD in the second quarter of 2015. The PD-LID study will be conducted at Parkinson's disease centers of excellence in the United States and Europe. This trial is a double-blind, placebo-controlled, four-way crossover, dose range finding, clinical study designed to evaluate dose response effect of repeated eltoprazine dosing on s afety, tolerability and dyskinesia severity using state-of-the-art rating scales, diaries and motion sensors. Pharmacokinetics and pharmacodynamics will also be evaluated.

The USPTO issues a Notice of Allowance after it makes a determination that a patent should be granted from a patent application.

About Eltoprazine

Eltoprazine is a small molecule 5HT1A/1B partial agonist in clinical development for the treatmen t of Parkinson's disease levodopa-induced dyskinesia (PD-LID), adult attention deficit hyperactivity disorder (ADHD), and Alzheimer's aggression. Eltoprazine has been evaluated in over 680 human subjects to date, and has a well-established safety profile. Eltoprazine was originally developed by Solvay Pharmaceuticals, now AbbVie, for the treatment of aggression. Solvay out-licensed the eltoprazine program to PsychoGenics. PsychoGenics licensed eltoprazine to Amarantus following successful proof-of-concept trials in PD-LID and adult ADHD.

About Parkinson's Disease and Levodopa-Induced Dyskinesia (PD-LID)

Parkinson's disease is a chronic, progressive neurodegenerative disorder that causes motor symptoms such as tremors, rigidity and slowed movements as well as non-motor symptoms including cognitive impairment, mood disorders and autonomic dysfunction. The Parkinson's Disease Foundation estimates that there are approximately one million people living with Parkinson's disease in the United States and seven to 10 million PD patients worldwide. The most commonly prescribed treatments for Parkinson's disease are levodopa-based therapies. In the body, levodopa is converted to dopamine to replace the dopamine loss caused by the disease. As dopamine neurons in the brain are lost the therapeutic efficacy of levodopa attenuates, and increased use is associated with a side effect of dyskinesias. These are involuntary, uncontrollable and often exaggerated and jerky movements. They are distinct from the static, rhythmic tremor as a symptom of Parkinson's disease. Levodopa-induced dysk inesia can be severely disabling, rendering patients unable to perform routine daily tasks.

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. AMBS' Therapeutics division has development rights to eltoprazine, a Phase 2b ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as m esencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS' Diagnostics division owns the rights to MSPrecise, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). AMBS also owns the discovery of neurotrophic factors (PhenoGuard) that led to MANF's discovery.

Samsung and Sharp are the experts, not me. They believe their phones needed it so they are building it. Apple will follow for sure.

I heard the same when we use to have analog cellphones; no one wanted a higher resolution screen because it was too sharp, look at where we are now.

Whether you want it or not, a 4K UHD resolution screen could be fitted to your next phone

Read more: http://www.digitaltrends.com/mobile/sharp-igzo-uhd-4k-smartphone-screen-news/#ixzz3a2M5nDV4

Also, the Era of 4K UHD Smartphones Begins This Year (2015)

http://www.businesskorea.co.kr/article/4220/higher-resolution-era-4k-uhd-smartphones-begins-next-year

FilmKaravan has more than a 1000 films catalog in Hindi and Regional Languages, representing 90% of the Indian Film Industry Content.

They mentioned that they have exclusive tie-ups with largest platforms and execute worldwide Day and Date release simultaneously to theatrical release in India. (this is huge).

Ultraflix will be for sure one of those content providers.

Attracting the Bolliwood followers was a great move; tons of viewers!

NTEK

We pierced the 50 day MA; we'll be back on the radar.

If you're a Star Wars fan and you're able to watch Harmy's descentrilized versions (Empire v2 and ROTJ v1), you'll see why NTEK couldn't pass on hiring him; he's a skillful young man.

He was recently mentioned in one of the episodes of This Week in Tech (#1 ranked technology podcast).

Cheers,

SF

David R. Foley to Self-Surrender on 6/9/2015 by 2pm to the BOP designated facility.

I hope he finds strength to overcome this difficult time.

NTEK is in good hands.

Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF

GlobeNewswire

8:05 AM ET
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 13/305,025 entitled, "Dopaminergic Neuronal Survival Promoting Factors and Uses Thereof." Upon issuance, the patent will provide additional intellectual property protection for MANF (mesencephalic-astrocyte-derived neurotrophic factor) protein therapy and cell therapy. The allowed patent claims cover compositions of matter and methods of use related to the Company's proprietary manufacturing process for synthetic MANF and its administration.

Nativ e MANF is currently under development for the treatment of orphan ocular indications, including retinitis pigmentosa (RP). Amarantus recently received orphan drug designation for MANF for the treatment in RP in the United States and in Europe. In addition, MANF proteins have demonstrated proof-of-concept in preclinical models to treat a wide range of conditions including retinal artery occlusion, glaucoma, macular degeneration, Parkinson's disease (PD), diabetes and ischemic heart disease, among others.

"This Notice of Allowance is another important element in our intellectual property strategy that we believe will allow us to fully exploit the fundamental value of the research and development ongoing for MANF, both internally and via our collaborations," said Gerald E. Commissiong, Pres ident & CEO of Amarantus. "MANF is being developed as a potential therapeutic intervention for orphan ocular diseases and other chronic disorders for which few, if any, viable disease-modifying treatment options exist."

"This important step further signals the Company's commitment to strengthening our industry-leading intellectual property portfolio surrounding MANF," said John W. Commissiong, Ph.D., Amarantus CSO and co-discoverer of MANF. "We will continue to strengthen our robust intellectual property estate to further protect and maintain our proprietary rights, which we believe will not only allow us to capitalize on the known opportunities for MANF development, but will also further entrench Amarantus as the leading company for new collaborations in light of emerging potential MANF applications."

The USPTO issues a Notice of Allowance after it makes a determination that a patent should be granted from a patent application.

About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)

MANF (mesencephalic-astrocyte-derived neurotrophic factor) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease, via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property around MANF, and is initially focusing on the development of MANF-based protein therapeutics. MANF, a naturally-occurring protein that reduces and prevents apoptosis (programmed cell death) in response to injury or disease, was discovered utilizing Amarantus' proprietary PhenoGuard Protein Discovery Engine.

MANF's lead indication is retinitis pigmentosa, and additional indications including Parkinson's disease, diabetes and Wolfram's syndrome are currently pursued. Further applications for MANF may include Alzheimer's disease, traumatic brain injury, myocardial infarction, antibiotic-induced ototoxicity and certain other rare orphan diseases currently under evaluation.

Where is David R. Foley?

The best NTEK pump in the last couple of years though. The kid had talent, can't deny that.

Trace it back. I'm sure you'll figure it out easily if you've been here long enough.

He's a promoter too. He stated it liked a year ago when he was pro NTEK.

What a scam! Report them to the SEC!

It seems like there will be many lawsuits regarding NTEK from both sides of the fence.

NanoTech Signs Licensing Agreement with Paramount Pictures to Offer "G.I. JOE: RETALIATION" on UltraFlix 4K Streaming Network

PR Newswire
3:49 PM ET

NanoTech Entertainment (OTCPINK: NTEK), a pioneer in bringing the Ultra HD experience to consumers, announced today a licensing agreement with Paramount Pictures that will bring the explosive global hit "G.I. JOE: RETALIATION" to UltraFlix(TM), NanoTech's all Ultra HD network. Under the agreement, the film will be available in Ultra HD beginning in April 2015.

http://photos.prnewswire.com/prnvar/20140929/149073

Called "a stunning, high-flying, super-charged blast of fun" (Shawn Edwards, FOX-TV), the $375+ million worldwide blockbuster "G.I. JOE: RETALIATION" explodes in Ultra HD on the UltraFlix network this month. "Born to play a G.I. JOE" (Scott Bowles, USA Today), Dwayne Johnson embodies ROADBLOCK and he and Channing Tatum "are a match made in action flick heaven" (James Oster, JoBlo.com) in this "cool ride" (Richard Corliss, Time) that is "awesome times 10!" (Shawn Edwards, FOX-TV). From Paramount Pictures and Metro-Goldwyn-Mayer Pictures, "G.I. JOE: RETALIATION" also stars action legend Bruce Willis as the original G.I. JOE, as well as Adrianne Palicki, D.J. Cotrona and Jonathan Pryce. In director Jon M. Chu's heart-pounding thrill ride, the G.I. JOE team not only faces off against its mortal enemy COBRA, it is also forced to contend with threats from within the government that jeopardize its very existence.

In addition to "G.I. JOE: RETALIATION," Ultra Flix now offers subscribers the largest library of crystal-clear 4K content, reinforcing its lead as the source for the world's largest and most diverse library of 4K VOD entertainment. To appeal to a broad audience, offerings range from sci-fi, action/thriller, comedy, drama and family movies to extreme sports videos, concerts, TV shows, and special events. UltraFlix also offers over 100 hours of free content.

To enhance the viewing experience, UltraFlix uses a variety of proprietary technologies with video compression, adaptive streaming and intelligent bandwidth management. These technologies enable UltraFlix to stream visually lossless 4K video with uninterrupted viewing at under 8Mbps, making it available to most North American and European internet subscribers today.

"We are very excited to continue offering the most visually stunning films to our UltraFlix subscribers," said Aaron Taylor, NanoTech's Executive Vice President of Sales & Marketing. "G.I. JOE: RETALIATION is an outstanding addition to our already exceptional lineup."

About UltraFlix

UltraFlix, the world's first dedicated 4K Ultra HD network, will enable subscribers to choose from hundreds of hours of video on demand pris tine 4K Ultra HD content in a broad range of genres and over 100 hours of free content. In addition to being available on NanoTech's award-winning Nuvola(TM) NP-1 streaming 4K Ultra HD media player, UltraFlix has also become the preferred 4K Smart TV App for leading 4K Smart TV manufacturers including Samsung, Sony, Vizio and others that are in the process of completing their testing and integration. Recently, UltraFlix powered the Best Buy's Ultra HD viewing events providing the content for locations throughout North America highlighting 4K Ultra HD TVs from Sony, Samsung and LG.

About Paramount Home Media Distribution

Paramount Home Media Distribution (PHMD) is part of Paramount Pictures Corporation (PPC), a global producer and distributor of filmed entertainment. PPC is a unit of Viacom (NASDAQ: VIAB, VIA), a leading content company with prominent and respected film, television and digital entertainment brands. The PHMD division oversees PPC's home entertainment, digital and television distribution activities worldwide. The division is responsible for the sales, marketing and distribution of home entertainment content on behalf of Paramount Pictures, Paramount Animation, Paramount Vantage, Paramount Classics, Insurge Pictures, MTV, Nickelodeon, Comedy Central and CBS and applicable licensing and servicing of certain DreamWorks Animation titles. PHMD additionally manages global licensing of studio content and distribution across worldwide digital and television distribution platforms including online, mobile and portable devices and emerging technologies.

About NanoTech Entertainment

Headquartered in San Jose, CA, the heart of Silicon Valley, NanoTech Entertainment is a technology company that focuses on all aspects of the entertainment industry. With seven technology business units, focusing on 3D, Content, Media & IPTV, Mobile Apps, and Manufacturing, the company has a unique business model. The company has a diverse portfolio of products and technology. NanoTech Media develops proprietary technology which it licenses to publishers for use in their products as well as creating and publishing unique content. NanoTech Media Technology includes the world's first 4K Ultra HD streaming solution. NanoTech Communications develops and sells proprietary apps and technology in the Mobile and Consumer space. Clear Memories is the global leader in 3D ice carving and manufacturing technology. 4K Studios creates digital 4K Ultra HD content using both licensed materials as well as original productions. Ultra Media Group focuses on the acquisition and licensing of content. UMG also develops and creates original programming and live events for use on NanoTech networks. More information about NanoTech Entertainment and its products can be found on the web at www.NTEK.com.

"Safe Harbor" Statement: This press release contains forward-looking statements, including expected industry patterns and other financial and business results that involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the sustainability of recent growth rates in of the company; the positioning of NanoTech Entertainment, Inc. in the market; ability to integrate both developed and acquired companies and technology; ability to retain key employees; ability to successfully market product offerings and customer acceptance of products; general market conditions, fluctuations in currency exchange rates, changes to systems and product strategy by vendors of systems; and whether NanoTech Entertainment, Inc. can successfully gain market share. Actual results may differ materially from those contained in the forward-looking statements in this press release. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.

NanoTech Entertainment, NanoTech Media, NanoTech Gaming Labs, NanoTech Communications, MagicScreen, 4K Studios, 4K Ultra HD logo, UltraFlix, NanoFlix, Nuvola GP-1, Nuvola NP-H1, Nuvola TV-U1, Nuvola NP-1, Nuvola NP-C, and ProFlix UHD and their associated logos are trademarks of NanoTech Entertainment. "The Future of Television" and "The Future of Entertainment" are Service Marks of NanoTech Entertainment. All rights reserved. All other marks are the property of their respective owners.

We missed you around here. What's the word on the street about NTEK?

Apparently there are people willing to pay for it, but you're right, no one in their right mind would do it.

Apple Approves $999.99 App That Allows The Apple IPhone 5s To Shoot 4K Video

HEVC stands for High Efficiency Video Coding, a new technology for compressing dense Ultra HD video signals so they fit easily on optical discs or through Internet streaming. The most up to date 4K Ultra HD TVs should have an HEVC decoding chip that will allow viewing of 4K Ultra HD programs streamed through their Smart TV platforms. But just like 3D and HD before it, 4K has a case of putting the hardware chicken before the software egg.

If you can track it down, Ultraflix hosts hundreds of hours of 4K nature documentaries, including 40 titles originally created for IMAX, dozens of concerts, videos from acts like AC/DC and Madonna, and hundreds of hours of sci-fi, action comedy, and drama.

One of the freshest new services in the game, M-Go's VOD service launched its new red 4k (just click the up coming page) library in an exclusive partnership with Samsung November 12 The service will begin with a modest offering of titles, including Sin City: A Dame to Kill For, The Giver, Power, Ghost in the Shell and Limitless.

The service is currently available in Nanotech's Nuvola NP-1 streaming box ($300) as well, theoretically allowing it to stream 4K UHD content to any 4K UHD TV, which is a big deal. And while today's Blu-ray discs will be used initially, you'll unfortunately have to buy a new 4K UHD Blu-ray player to play the new content. The Digital Cinema Initiatives consortium established a standard resolution of 4096 pixels × 2160 lines (8.8 megapixels, aspect ratio ~17:9) for 4K film projection. The DCI 4K standard has twice the horizontal and vertical resolution of DCI 2K, with four times as many pixels overall.

With Blu-ray, you got everyone working together - you had movies appearing on it (including much back-catalogue being re-mastered for it), you had a combined push with HD resolutions. What will be really interesting (to me) are some of the techniques used to re-master old content to 4K formats. This makes sense seeing as the resolution of 3840×2160 is not the same as Digital Cinema 4K (4096×2160), and the industry is, on the whole, moving away from the 4K" moniker. It's far more likely that a more practical range of colors - such as those specified in the Digital Cinema Initiatives P3 gamut currently in use in movie theaters - will end up being used.

http://dpoint.vanlibero.com/index.php?document_srl=9193&mid=board_aXJl57&listStyle=viewer